JP2016043272A - 眼組織の架橋結合 - Google Patents
眼組織の架橋結合 Download PDFInfo
- Publication number
- JP2016043272A JP2016043272A JP2015165346A JP2015165346A JP2016043272A JP 2016043272 A JP2016043272 A JP 2016043272A JP 2015165346 A JP2015165346 A JP 2015165346A JP 2015165346 A JP2015165346 A JP 2015165346A JP 2016043272 A JP2016043272 A JP 2016043272A
- Authority
- JP
- Japan
- Prior art keywords
- nanoparticles
- photosensitizer
- linking
- cross
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004132 cross linking Methods 0.000 title claims abstract description 54
- 239000002105 nanoparticle Substances 0.000 claims abstract description 169
- 239000003504 photosensitizing agent Substances 0.000 claims abstract description 132
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical group OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 53
- 230000005855 radiation Effects 0.000 claims description 44
- 210000004087 cornea Anatomy 0.000 claims description 28
- 239000006229 carbon black Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 230000004913 activation Effects 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical class C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 claims description 10
- 229910003472 fullerene Inorganic materials 0.000 claims description 9
- 201000002287 Keratoconus Diseases 0.000 claims description 7
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 5
- 208000018672 Dilatation Diseases 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000011852 carbon nanoparticle Substances 0.000 claims description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 2
- 102000004669 Protein-Lysine 6-Oxidase Human genes 0.000 claims description 2
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 claims description 2
- 108060008539 Transglutaminase Proteins 0.000 claims description 2
- 150000001299 aldehydes Chemical class 0.000 claims description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 2
- FEKRFYZGYUTGRY-UHFFFAOYSA-N n'-ethylmethanediimine Chemical compound CCN=C=N FEKRFYZGYUTGRY-UHFFFAOYSA-N 0.000 claims description 2
- 102000003601 transglutaminase Human genes 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 description 77
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 26
- 229960002477 riboflavin Drugs 0.000 description 26
- 239000002151 riboflavin Substances 0.000 description 25
- 235000019192 riboflavin Nutrition 0.000 description 25
- 210000001508 eye Anatomy 0.000 description 24
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 19
- 239000013543 active substance Substances 0.000 description 12
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 210000000981 epithelium Anatomy 0.000 description 7
- 210000002159 anterior chamber Anatomy 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 210000003683 corneal stroma Anatomy 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 239000010931 gold Substances 0.000 description 5
- 229910052737 gold Inorganic materials 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000002041 carbon nanotube Substances 0.000 description 4
- 229910021393 carbon nanotube Inorganic materials 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000003365 glass fiber Substances 0.000 description 4
- 238000012014 optical coherence tomography Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920001661 Chitosan Polymers 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000013480 data collection Methods 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000002096 quantum dot Substances 0.000 description 3
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 201000009310 astigmatism Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004045 bowman membrane Anatomy 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000000412 dendrimer Substances 0.000 description 2
- 229920000736 dendritic polymer Polymers 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000005670 electromagnetic radiation Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229910002804 graphite Inorganic materials 0.000 description 2
- 239000010439 graphite Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002048 multi walled nanotube Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 239000011241 protective layer Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000002109 single walled nanotube Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000004071 soot Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000011882 ultra-fine particle Substances 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000004329 axial myopia Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000002555 descemet membrane Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000011554 ferrofluid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000012977 invasive surgical procedure Methods 0.000 description 1
- 125000000686 lactone group Chemical group 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000002073 nanorod Substances 0.000 description 1
- 231100000623 nanotoxicology Toxicity 0.000 description 1
- 239000002071 nanotube Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001443 photoexcitation Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/067—Radiation therapy using light using laser light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F2009/00853—Laser thermal keratoplasty or radial keratotomy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F2009/00861—Methods or devices for eye surgery using laser adapted for treatment at a particular location
- A61F2009/00872—Cornea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F2009/00878—Planning
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0626—Monitoring, verifying, controlling systems and methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Prostheses (AREA)
- Steroid Compounds (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
続く図面を参照して、特定の例示的な実施形態がより詳細に説明される。図面において、理解を高めるために、個々の要素がより正確に作られているが、これは、示される主題を限定するよう意図されるものではない。例えば、UV光源(22)は、様々な波長領域の光を発するように設定することもできる。
IRレーザー放射によって眼組織に切開が作成される(図2a)。リボフラビンおよびカーボンブラックナノ粒子が切開に導入される(図2b)。その後、眼組織およびナノ粒子によって吸収されるリボフラビンが、360nm〜370nmの領域のUV放射によって活性化される(図2c)。硬化時間は、ナノ粒子なしのリボフラビンのみの適用と比べて大幅に短縮される。
リボフラビンおよびカーボンブラックナノ粒子が眼組織に適用される(図3a)。待ち時間後、リボフラビンおよびナノ粒子は、組織内に拡散する(図3b)。その後、眼組織およびナノ粒子によって吸収されたリボフラビンは、360nm〜370nmの領域のUV放射によって活性化される(図3c)。硬化時間は、ナノ粒子なしのリボフラビンのみの適用と比べて大幅に短縮される。
IRレーザー放射によって眼組織に切開が作成される(図4a)。リボフラビンおよびカーボンブラックナノ粒子が、切開に導入される(図4b)。その後、眼組織およびナノ粒子によって吸入されたリボフラビンは、1064nmの領域のIR照射によって活性化される(図4c)。硬化時間は、ナノ粒子なしのリボフラビンのみの適用と比べて大幅に短縮される。
[1] Brianna Deane, Nanodiamond-embedded contact lenses improve glaucoma treatment, Science and Technology, UCLA, 13 February 2014.
[2] P. Chakravarty et al, Delivery of molecules into cells using carbon nanoparticles activated by femtosecond laser pulses, Nature Nanotechnology, 5, 607-611, (2010).
[3] F. Rossi et al., Laser Activated Gold Nanorods for the Photothermal Treatment of Cancer, Excerpt from the Proceedings of the 2012 Comsol Conference in Milan.
[4] M. Tachibana, Characterization of Laser-Induced Defects and Modification in Carbon Nanotubes by Raman Spectroscopy, Physical and Chemical Properties of Carbon, 2013, Nanotubes, http://dx.doi.org/10.5772/52091.
[5] Yamakoshi et al., Active oxygen species generated from photo-excited fullerene (C-60) as potential medicines: O2 - versus 1O2. J. Am. Chem. Soc. 2003, 125, 12803-9.
[6] A. Sengupta, Laser-Activated Carbon Nanoparticle Cellular Damage and Prevention, Pharmaceutical Discovery, Development and Manufacturing Forum, AIChE Annual Meeting, 7 November 2013.
[7] A. Sengupta, Efficient intracellular delivery of molecules with high cell viability using nanosecond-pulsed laser-activated carbon nanoparticles, ACS Nano. 2014 Mar 25;8(3):2889-99. doi: 10.1021/nn500100x.
[8] W. De Jong, P. JA Borm, Drug delivery and nanoparticles: Applications and Hazards, Int. J. Nanomdedicine, June 2008, 3(2), 133-149.
[9] Donaldson et al., The pulmonary toxicology of ultrafine particles, J. Aerosol. Med. 2002, 15, 213-20.
[10] Donaldson et al., Nanotoxicology, Occup. Environ. Med. 2005, 61, 727-28.
[11] Oberdoerster et al., Nanotoxicolgy: An emerging discipline evolving from studies of ultrafine particles, Einvorn Health erspect., 2005, 113, 823-39.
[12] Borm et al 2006, The Potential risks of nanomaterials: a review carried out for ECETOC, PArt. Fiber Toxicol., 2006, 3, 11.
Claims (13)
- 眼組織の架橋結合のためのデバイスであって、
光増感剤およびナノ粒子を前記眼組織に導入または適用するように設計される機器と、
前記眼組織の架橋結合のために、導入または適用された前記光増感剤、および/または導入または適用された前記ナノ粒子を活性化するように設計される光源と、を備える、デバイス。 - 前記光源は、UV光源を含む、請求項1に記載のデバイス。
- 架橋結合制御システムを備え、
制御コンピュータが、
前記光増感剤および前記ナノ粒子の前記導入または適用を制御する、および/または
前記光増感剤および/または前記ナノ粒子の前記活性化を制御する、
ようにプログラムされる、請求項1または2に記載のデバイス。 - 前記眼組織に前記光増感剤および/または前記ナノ粒子を前記導入または適用するための少なくとも1つの切開を作成するように設計される、システムをさらに備える、請求項1〜3のいずれか1項に記載のデバイス。
- 前記システムは、
レーザー放射源と、
前記眼組織に対して前記レーザー放射を誘導および集束するためのシステムと、
前記システムを制御するためのコンピュータであって、前記眼組織内に延在し、かつ前記眼の表面の少なくとも1つの開口部に接続される、少なくとも1つのチャネルが前記眼組織に作成されるように、レーザー放射を制御するようにプログラムされる、コンピュータと、
を備える、請求項5に記載のデバイス。 - 前記レーザー放射源は、300〜1900ナノメートル(nm)の波長領域の光を提供するように設計される、請求項5に記載のデバイス。
- 前記光増感剤は、リボフラビン(ビタミンB2)、リジル酸化酵素、トランスグルタミナーゼ、糖アルデヒド、エチルカルボジイミド、グルタルアルデヒド、ホルムアルデヒド、またはそれらの混合物を含むか、またはそれらから選択される、請求項1〜6のいずれか1項に記載のデバイス。
- 前記ナノ粒子は、前記光増感剤による架橋結合を触媒するのに適している、請求項1〜7のいずれか1項に記載のデバイス。
- 前記ナノ粒子は、カーボンナノロッド、フラーレン、および/またはカーボンブラックナノ粒子を含むか、またはそれらから選択される、請求項1〜8のいずれか1項に記載のデバイス。
- 前記カーボンナノ粒子は、1〜100nmの領域のサイズを有する、請求項9に記載のデバイス。
- 眼組織の架橋結合のための光増感剤およびナノ粒子を含む、医薬組成物。
- 拡張症もしくは円錐角膜の治療のための、または角膜移植もしくはLASIKの処置において使用するための、請求項1〜10のいずれか1項に記載のデバイスおよび/または請求項11に記載の医薬組成物の使用。
- 眼組織の架橋結合のための方法であって、
光増感剤およびナノ粒子を角膜に導入または適用するステップと、
前記眼組織の架橋結合のために、導入または適用された前記光増感剤、および/または導入または適用された前記ナノ粒子を活性化するのに適した波長を有する光を提供するステップと、を有する、方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102014012675.7 | 2014-08-26 | ||
DE102014012675.7A DE102014012675A1 (de) | 2014-08-26 | 2014-08-26 | Vernetzung von Augengewebe |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016043272A true JP2016043272A (ja) | 2016-04-04 |
JP6697233B2 JP6697233B2 (ja) | 2020-05-20 |
Family
ID=53773174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015165346A Active JP6697233B2 (ja) | 2014-08-26 | 2015-08-25 | 眼組織の架橋結合 |
Country Status (13)
Country | Link |
---|---|
US (1) | US9907977B2 (ja) |
EP (1) | EP2990016B1 (ja) |
JP (1) | JP6697233B2 (ja) |
KR (1) | KR20160024770A (ja) |
CN (1) | CN105380745B (ja) |
AU (2) | AU2015202642A1 (ja) |
BR (1) | BR102015017380A2 (ja) |
CA (1) | CA2891783C (ja) |
DE (1) | DE102014012675A1 (ja) |
ES (1) | ES2724334T3 (ja) |
MX (1) | MX356648B (ja) |
RU (1) | RU2703703C2 (ja) |
TR (1) | TR201906047T4 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9622911B2 (en) | 2010-09-30 | 2017-04-18 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
EP2830627B1 (en) | 2012-03-29 | 2024-05-01 | Epion Therapeutics, Inc. | Ocular treatment solutions, delivery devices and delivery augmentation methods |
US9566301B2 (en) | 2012-03-29 | 2017-02-14 | Cxl Ophthalmics, Llc | Compositions and methods for treating or preventing diseases associated with oxidative stress |
US11207410B2 (en) | 2015-07-21 | 2021-12-28 | Avedro, Inc. | Systems and methods for treatments of an eye with a photosensitizer |
US10940042B2 (en) | 2015-10-23 | 2021-03-09 | The Trustees Of Columbia University In The City Of New York | Laser induced collagen crosslinking in tissue |
AU2016396661B2 (en) | 2016-03-08 | 2023-01-19 | University Of Utah Research Foundation | Cross-linking agents and associated methods |
WO2017180851A1 (en) | 2016-04-13 | 2017-10-19 | Avedro, Inc. | Systems and methods for delivering drugs to an eye |
WO2017214604A1 (en) | 2016-06-10 | 2017-12-14 | The Trustees Of Columbia University In The City Of New York | Devices, methods, and systems for detection of collagen tissue features |
CN106236372A (zh) * | 2016-08-17 | 2016-12-21 | 浙江大学 | 一种数字化角膜交联调节角膜曲率半径的方法及设备 |
RU2646452C1 (ru) * | 2016-11-07 | 2018-03-05 | Государственное бюджетное учреждение "Уфимский научно-исследовательский институт глазных болезней Академии наук Республики Башкортостан" | Офтальмологическое средство для ультрафиолетового кросслинкинга роговицы |
RU173903U1 (ru) * | 2017-02-07 | 2017-09-18 | Государственное бюджетное учреждение "Уфимский научно-исследовательский институт глазных болезней Академии наук Республики Башкортостан" | Излучатель устройства для перекрестного сшивания коллагена склеры |
RU2645931C1 (ru) * | 2017-06-29 | 2018-02-28 | Федеральное государственное бюджетное учреждение "Московский научно-исследовательский институт глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации | Способ лечения кератэктазий |
EP3668368A4 (en) * | 2017-08-18 | 2021-08-18 | The General Hospital Corporation | BRILLOUIN SPECTROSCOPY AND TISSUE IMAGING SYSTEMS AND METHODS |
US11666481B1 (en) | 2017-12-01 | 2023-06-06 | The Trustees Of Columbia University In The City Of New York | Diagnosis and treatment of collagen-containing tissues |
KR20240090673A (ko) * | 2018-03-02 | 2024-06-21 | 렌사르, 인크. | 노안을 다루고, 완화시키고 역전시키기 위한 레이저 방법 및 시스템 |
CN108403292B (zh) * | 2018-03-29 | 2020-06-19 | 牟国营 | 一种巩膜交联设备及使用方法 |
WO2020219931A1 (en) * | 2019-04-26 | 2020-10-29 | The Regents Of The University Of California | Nonlinear optical device for micro-machining of the corneal epithelium |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005538033A (ja) * | 2001-12-04 | 2005-12-15 | ナノスペクトラ バイオサイエンセズ,インク. | 過剰なあるいは不適切な新脈管形成によって特徴付けられる病状の治療 |
JP3158398U (ja) * | 2008-12-01 | 2010-04-02 | セロス・メディカル・エルエルシイ | インサイチュでのuv/リボフラビン眼治療システム |
US20100210996A1 (en) * | 2001-11-07 | 2010-08-19 | Peyman Gholam A | Method for laser correction of refractive errors of an eye with a thin cornea |
WO2011152861A2 (en) * | 2010-06-01 | 2011-12-08 | Gholam Peyman | Laser-based methods and systems for performing corneal surgery |
JP2012502668A (ja) * | 2008-09-19 | 2012-02-02 | アヴェドロ・インコーポレーテッド | 眼治療システム |
JP2013236905A (ja) * | 2012-05-16 | 2013-11-28 | Iroc Innocross Ag | 光増感剤を導入するために眼を切開する装置および屈折矯正手術の方法 |
WO2014114359A1 (en) * | 2013-01-28 | 2014-07-31 | Wavelight Gmbh | Apparatus for corneal crosslinking |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6530944B2 (en) * | 2000-02-08 | 2003-03-11 | Rice University | Optically-active nanoparticles for use in therapeutic and diagnostic methods |
US7073510B2 (en) * | 2000-02-11 | 2006-07-11 | The General Hospital Corporation | Photochemical tissue bonding |
US9681942B2 (en) * | 2001-11-07 | 2017-06-20 | Gholam A. Peyman | Method for prevention of rejection and sever encapsulation of a supportive or functioning implant |
JP2008519642A (ja) * | 2004-11-12 | 2008-06-12 | ケーピーイー リミテッド | ナノ粒子を介した超音波治療および診断影像法 |
AU2007272558B2 (en) * | 2006-07-12 | 2010-12-09 | Novartis Ag | Actinically crosslinkable copolymers for manufacturing contact lenses |
US20110052672A1 (en) * | 2008-01-16 | 2011-03-03 | Sunil Krishnan | Treatments of disease or disorders using nanoparticles for focused hyperthermia to increase therapy efficacy |
FR2952306B1 (fr) * | 2009-11-09 | 2012-03-30 | Creaspine | Composition aqueuse utilisee dans le traitement de la reparation de tissu conjonctif fibreux par laser |
WO2011084863A2 (en) * | 2010-01-07 | 2011-07-14 | Cheetah Omni, Llc | Fiber lasers and mid-infrared light sources in methods and systems for selective biological tissue processing and spectroscopy |
AU2011210536A1 (en) * | 2010-02-01 | 2012-09-13 | Conversion Energy Enterprises Inc. | Methods and devices for crosslinking of corneal collagen and for treatment of disorders of the eye |
CN102917676A (zh) * | 2010-04-30 | 2013-02-06 | 塞罗斯医学有限责任公司 | 使用组合的方式治疗眼组织的方法和装置 |
EP2407132B1 (de) * | 2010-06-24 | 2014-04-30 | WaveLight GmbH | Vorrichtung zum Präparieren eines Auges für das Einbringen von Photosensibilisator |
CN103429266A (zh) * | 2010-11-26 | 2013-12-04 | 约翰内斯堡金山大学 | 药物递送装置 |
WO2012135073A2 (en) * | 2011-03-25 | 2012-10-04 | Board Of Trustees Of Michigan State University | Adaptive laser system for ophthalmic use |
US10463541B2 (en) * | 2011-03-25 | 2019-11-05 | Lensar, Inc. | System and method for correcting astigmatism using multiple paired arcuate laser generated corneal incisions |
RU2456971C1 (ru) * | 2011-04-19 | 2012-07-27 | Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" | Способ лечения прогрессирующего кератоконуса |
JP6275707B2 (ja) * | 2012-06-20 | 2018-02-07 | フランク・グー | 粘膜付着性ナノ粒子送達系 |
US20160151202A1 (en) * | 2013-07-19 | 2016-06-02 | The General Hospital Corporation | System, method and arrangements for modifying optical and mechanical properties of biological tissues |
-
2014
- 2014-08-26 DE DE102014012675.7A patent/DE102014012675A1/de active Pending
-
2015
- 2015-05-13 US US14/711,640 patent/US9907977B2/en active Active
- 2015-05-15 CA CA2891783A patent/CA2891783C/en active Active
- 2015-05-22 AU AU2015202642A patent/AU2015202642A1/en not_active Abandoned
- 2015-06-09 ES ES15171286T patent/ES2724334T3/es active Active
- 2015-06-09 TR TR2019/06047T patent/TR201906047T4/tr unknown
- 2015-06-09 EP EP15171286.6A patent/EP2990016B1/en active Active
- 2015-07-01 CN CN201510377979.9A patent/CN105380745B/zh active Active
- 2015-07-21 BR BR102015017380A patent/BR102015017380A2/pt not_active Application Discontinuation
- 2015-08-20 KR KR1020150117159A patent/KR20160024770A/ko unknown
- 2015-08-25 JP JP2015165346A patent/JP6697233B2/ja active Active
- 2015-08-25 RU RU2015135997A patent/RU2703703C2/ru not_active IP Right Cessation
- 2015-08-25 MX MX2015011056A patent/MX356648B/es active IP Right Grant
-
2017
- 2017-03-21 AU AU2017201905A patent/AU2017201905B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100210996A1 (en) * | 2001-11-07 | 2010-08-19 | Peyman Gholam A | Method for laser correction of refractive errors of an eye with a thin cornea |
JP2005538033A (ja) * | 2001-12-04 | 2005-12-15 | ナノスペクトラ バイオサイエンセズ,インク. | 過剰なあるいは不適切な新脈管形成によって特徴付けられる病状の治療 |
JP2012502668A (ja) * | 2008-09-19 | 2012-02-02 | アヴェドロ・インコーポレーテッド | 眼治療システム |
JP3158398U (ja) * | 2008-12-01 | 2010-04-02 | セロス・メディカル・エルエルシイ | インサイチュでのuv/リボフラビン眼治療システム |
WO2011152861A2 (en) * | 2010-06-01 | 2011-12-08 | Gholam Peyman | Laser-based methods and systems for performing corneal surgery |
JP2013236905A (ja) * | 2012-05-16 | 2013-11-28 | Iroc Innocross Ag | 光増感剤を導入するために眼を切開する装置および屈折矯正手術の方法 |
WO2014114359A1 (en) * | 2013-01-28 | 2014-07-31 | Wavelight Gmbh | Apparatus for corneal crosslinking |
Also Published As
Publication number | Publication date |
---|---|
JP6697233B2 (ja) | 2020-05-20 |
DE102014012675A1 (de) | 2016-03-03 |
CN105380745A (zh) | 2016-03-09 |
EP2990016B1 (en) | 2019-03-13 |
KR20160024770A (ko) | 2016-03-07 |
BR102015017380A2 (pt) | 2016-04-19 |
MX356648B (es) | 2018-06-06 |
CN105380745B (zh) | 2020-05-08 |
RU2703703C2 (ru) | 2019-10-21 |
AU2017201905B2 (en) | 2018-01-18 |
CA2891783A1 (en) | 2016-02-26 |
US9907977B2 (en) | 2018-03-06 |
RU2015135997A3 (ja) | 2019-03-27 |
TR201906047T4 (tr) | 2019-05-21 |
US20160059032A1 (en) | 2016-03-03 |
EP2990016A1 (en) | 2016-03-02 |
RU2015135997A (ru) | 2017-03-02 |
MX2015011056A (es) | 2016-10-25 |
AU2015202642A1 (en) | 2016-03-17 |
ES2724334T3 (es) | 2019-09-10 |
CA2891783C (en) | 2021-05-25 |
AU2017201905A1 (en) | 2017-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6697233B2 (ja) | 眼組織の架橋結合 | |
Hoy et al. | Clinical ultrafast laser surgery: recent advances and future directions | |
Yun et al. | Light in diagnosis, therapy and surgery | |
Vanerio et al. | Biomedical applications of photo-and sono-activated Rose Bengal: A review | |
Raeesi et al. | Improving nanoparticle diffusion through tumor collagen matrix by photo-thermal gold nanorods | |
Li et al. | Immunophilin FK506 loaded in chitosan guide promotes peripheral nerve regeneration | |
Tang et al. | Ocular nanomedicine | |
EP2948113B1 (en) | Apparatus for corneal crosslinking | |
US11925686B2 (en) | Materials for phototherapies of ophthalmic diseases | |
EP3288588A1 (en) | Improved cross-linking agents of collagen fibers for the use in the treatment of corneal ectasia | |
US20130310728A1 (en) | Device for dissecting an eye for the introduction of photosensitizer and method of refractive surgery | |
Obiweluozor et al. | Short duration cancer treatment: Inspired by a fast bio-resorbable smart nano-fiber device containing NIR lethal polydopamine nanospheres for effective chemo–photothermal cancer therapy | |
US20150119792A1 (en) | Light degradable drug delivery system for ocular therapy | |
CN103083133A (zh) | 一种基于金纳米棒的眼底病激光光热治疗系统 | |
US11696952B2 (en) | Nanocapsule-based ocular therapy | |
Matteini et al. | Laser welding of biological tissue: mechanisms, applications and perspectives | |
JP6100008B2 (ja) | 生体用インプラント | |
Schulze | Medical Applications of Lasers: Diversity is Key to Success: Therapy, clinical tests or device fabrication: Diverse lasers ensure optimum results | |
Steen et al. | Biomedical Laser Processes and Equipment | |
Naves et al. | Biofunctional Three-Dimensional Nanofibrous Surface for Tissue Engineering and Apoptotic Carcinogenic Approach | |
Matteini et al. | Biofilms of chitosan-gold nanorods as a novel composite for the laser welding of biological tissue | |
Clutter II | Stimulation-Responsive Materials for the Treatment of Disordered Tissues | |
Dahman et al. | Nanotechnology and its Applications in Biomedical Engineering | |
Dahman et al. | 1 Nanotechnology and | |
Jain | Nanomedicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180803 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190611 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190806 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191105 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191203 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20191227 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20200120 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20200212 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200227 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200407 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200424 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6697233 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |